Leerink has upgraded Gilead Sciences (NASDAQ:GILD) to outperform, citing the growth outlook for its PrEP treatment ...
Zacks.com on MSN6h
Gilead, MRK Report Data From Investigational Combination Study for HIVGilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational ...
Leerink upgraded Gilead (GILD) to Outperform from Market Perform with a price target of $96, up from $74. The stock has appreciated following ...
As you can see from the chart above the percentage of shares that are sold short for Gilead Sciences has declined since its ...
Lenacapavir is a long-acting pre-exposure prophylaxis (PrEP) product, a treatment that works by stopping HIV from getting ...
(Reuters) -Gilead Sciences said on Friday it was voluntarily withdrawing its drug, Trodelvy, for patients with a type of ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
1d
Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...
Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable ...
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
On Friday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $84.95 which represents a slight increase of $0.28 or 0.33% from the prior close of $84.67. The stock opened at $84 ...
Shares of Gilead Sciences Inc. GILD inched 0.33% higher to $84.95 Friday, on what proved to be an all-around great trading ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback